Akamis Bio Is A Clinical Stage Oncology Company Based In Cambridgemassachusettsit Focuses On Developing Innovative Cancer Treatments Through Its Proprietary Tumor Specific Immuno Gene Therapyt Signa Platformthe Company Aims To Enhance The Immune System S Ability To Recognize And Eliminate Cancer Cellspositively Impacting The Lives Of Patients With Cancer Founded In 2010 And Previously Known As Psioxus Therapeuticsakamis Bio Specializes In Solid Tumor Targeted T Signatherapeuticsits Lead Programng 350Ais An Immuno Stimulatory Tumor Gene Therapy Currently In Phase 1 Clinical Studies For Patients With Metastatic Or Advanced Epithelial Tumorsthe Company Collaborates With Prominent Organizations In The Immuno Oncology Fieldincluding Merck And The Cancer Research Instituteto Advance Its Research And Development Effortsakamis Bio Has Raised $182 69 Million In Fundingreflecting Strong Interest In Its Innovative Approach To Cancer Treatment
